Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225 Journal Article
| Author: | Hollywood, E. |
| Article Title: | Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225 |
| Abstract: | OBJECTIVES: To review the clinical safety experience of the monoclonal antibody IMC-C225, focusing on two clinically important adverse events: acne-like rash and allergic reactions. In addition, practical administration issues are discussed. DATA SOURCES: Research articles. CONCLUSIONS: IMC-C225 administration is well tolerated and adverse events are mild and manageable. IMC-C225 can be safely and conveniently administered once weekly in outpatient settings. IMPLICATIONS FOR NURSING PRACTICE: Because nurses will be involved with administration of IMC-C225 in the clinical setting, they must understand and be prepared to manage the acute and long-term adverse events associated with this agent. |
| Keywords: | treatment outcome; middle aged; clinical trial; review; case report; multimodality cancer therapy; antineoplastic agents; combined modality therapy; antineoplastic agent; drug eruption; epidermal growth factor receptor; colonic neoplasms; receptor, epidermal growth factor; cetuximab; monoclonal antibody; drug hypersensitivity; rash; antibodies, monoclonal; drug antagonism; chemically induced disorder; colon tumor; drug monitoring; clinical trials; drug eruptions; exanthema; humans; human; male |
| Journal Title: | Seminars in Oncology Nursing |
| Volume: | 18 |
| Issue: | Suppl.2 |
| ISSN: | 0749-2081 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2002-05-01 |
| Start Page: | 30 |
| End Page: | 35 |
| Language: | English |
| PUBMED: | 12053862 |
| PROVIDER: | scopus |
| DOI: | 10.1053/sonu.2002.33070 |
| DOI/URL: | |
| Notes: | Export Date: 14 November 2014 -- Source: Scopus |
